Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed derivatives with pyrimidine-fused cyclic structures acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndromes.